Pharmaceuticals

Trevi Therapeutics

Trevi Therapeutics released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0906 (forecast USD -0.0722)

Trevi Therapeutics to Release FY2026 Q1 Earnings on May 5 After-Market EST, Forecast EPS -0.0722 USD

Trevi Therapeutics Completes $173 Million Public Offering

Trevi Therapeutics released FY2025 earnings on March 17 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3173 (forecast USD -0.3677)

Trevi Therapeutics released FY2025 Q4 earnings on March 17 After-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0571 (forecast USD -0.0988)

Trevi Therapeutics to release FY2025 Q4 earnings on March 17 After-Market EST, forecast EPS USD -0.0988

Trevi Therapeutics Plans to Initiate Chronic Cough Clinical Trials and Appoint New CFO

Trevi Therapeutics Reports Q3 Earnings Improvement and Stock Surge

Trevi Therapeutics released FY2025 Q3 earnings on November 13 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0813 (forecast USD -0.0977)

Trevi Therapeutics released FY2025 9 Months Earnings on November 13 After-Market EST, with actual revenue of USD 0 and EPS of USD -0.2636

Trevi Therapeutics to Release FY2025 Q3 Earnings on November 13 After-Market (EST), Forecast EPS -0.0977 USD

JonesTrading Reiterates Buy Rating for Trevi Therapeutics

Trevi Therapeutics released FY2025 Q2 earnings on August 7 After-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0943 (forecast USD -0.0988)

Trevi Therapeutics released FY2025 Semi-Annual earnings on August 7 After-Market EST, actual revenue USD 0, actual EPS USD -0.1825

Trevi Therapeutics to Release FY2025 Q2 Earnings on August 7 After-Market EST, Forecast EPS -0.0988 USD

Trevi Therapeutics Attends Leerink Partners Industry Forum

Kaskela Law LLC Investigating Trevi Therapeutics, Inc.

Trevi Therapeutics Holds Annual Shareholders Meeting and Approves Multiple Resolutions

Trevi Therapeutics Completes $115 Million Underwritten Public Offering

Trevi Therapeutics Announces Development of New Drug Haduvio for IPF Chronic Cough

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

TRVI

ARKG

LABU

SBIO

Trevi Therapeutics (NASDAQ:TRVI) is advancing Haduvio, its extended-release formulation of nalbuphine, targeting chronic cough indications. The company plans to initiate Phase 3 trials for idiopathic pulmonary fibrosis (IPF) cough this quarter, with data readouts expected in 2027-2028. Trevi's commercial strategy focuses on a specialty model for pulmonologists, estimating a market potential of $5 billion to $12 billion for IPF cough and over $20 billion for treatment-resistant chronic cough. The company aims for Haduvio to achieve peak sales of $6 billion across these indications.

Market Beat

iShares US Pharma

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

VG Health

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

VanEck Biotech ETF

Health Care Select Sector SPDR

SPDR S&P Biotech

Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030

PILL

Equities researchers at HC Wainwright have lowered their FY2030 earnings estimates for Trevi Therapeutics (NASDAQ:TRVI) from $0.79 to $0.70 per share. The firm maintains a "Buy" rating with a target price of $21.00. Other analysts have varied opinions, with Morgan Stanley and Needham & Company also issuing buy ratings but with different price targets. Trevi's stock has seen a recent decline of 2.7%, opening at $14.26, and has a market cap of $1.83 billion. The company focuses on developing non-opioid therapies for pain management.

Invesco Dorsey Wright Healthcare Momentum ETF

Direxion Pharma & Medical Bull 3X

Morgan Stanley

Alliance HC

REPUBLIC HC

Hancock Whitney

Nano Labs

Weis Markets

Carl Zeiss Meditec AG

NEUBERGER BERMAN REAL ES-W/I

Landbridge Co LLC

Chemours

New England Real Asso

Jewett-Cameron

TJGC

D. BORAL ARC ACQUISITION I CORP. C/WTS 23/07/2030(TO PUR COM)

D Boral ARC Acquisition I

D Boral ARC Acquisition I - Unit

CHINA EB LTD

Arcadian Asset

SC ASSETS HLDGS - D

Rit Capital Partners PLC

Hennessy Capital Investment Corp VII

Hennessy Capital Investment Corp VII - Unit

Virtus Investment

Artisan Partners Asset Management 

VGI Partners Global Investments Ltd.

Kennedy-Wilson

Annaly Capital Mgmt

Sun Capital Management Corp.

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Hancock Whitney Pref Share HWCPZ 6.25 06/15/60

China Everbright Water

EB GRAND CHINA

ANNALY CAPITAL MANAGEMENT INC 6.95% FXD FLTG CUM RED PFD SR F 30/09/22

ANNALY CAPITAL MANAGEMENT INC 8.875 CUM PREF SER J

ANNALY CAPITAL MANAGEMENT INC 6.750% FXD TO FTG RATE CUM RED PRF SR I

ANNALY CAPITAL MANAGEMENT INC 6.50 CUM RED PFD STK FIX FLT SER G USD25

Research Analysts Set Expectations for TRVI FY2030 Earnings

Stifel Nicolaus analyst Annabel Samimy has maintained a Buy rating on Trevi Therapeutics (TRVI) with a price target of $18.00. The analyst has an average return of 17.1% and a success rate of 50.79% on her stock recommendations. The overall analyst consensus for Trevi Therapeutics is a Strong Buy, with an average price target of $22.14.

Tip Ranks

Stifel Financial

Viking Therap

Regenxbio

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)

Analyst Serge Belanger from Needham has reiterated a Buy rating on Trevi Therapeutics, lowering the price target to $23. The decision is based on the company's advancing clinical pipeline, including four late-stage studies of Haduvio set for 2026. Initial efficacy data is expected in 2027. Belanger notes Trevi's solid financial position, with approximately $334 million in cash to support operations until 2030. He has an average return of 13.4% and a 50.60% success rate on recommended stocks.

GlaxoSmithKline plc

Viridian Therapeutics

Esperion Therap

GSK plc Sponsored ADR

Analyst Reiterates Buy on Trevi Therapeutics, Slightly Lowers Price Target to $23 Amid Advancing Haduvio Pipeline

Earnings Watch

Trevi Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Trevi Therapeutics (NASDAQ:TRVI) reported its Q1 2026 earnings, highlighting an adaptive Phase 2/3 design for clinical trials and the addition of 10 new staff members, including a pulmonologist. The company remains optimistic about its competitive position in the RCC space, anticipating future data readouts in late 2024. Management emphasized their capability in managing multiple programs effectively, while also addressing potential competition from other drugs in the market. The company is focused on addressing the unmet needs of patients in this area.

benzinga_article

Trevi Therapeutics Q1 2026 Earnings Call Transcript

Trevi Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0

Trevi Therapeutics(TRVI.US)